Similar articles

• Treatment to prevent hepatitis B virus reactivation in patients with lymphoma receiving chemotherapy--reply.

  Lin T, Huang H, Li X. Lin T, et al. JAMA. 2015 Mar 24-31;313(12):1270. doi: 10.1001/jama.2015.1444. JAMA. 2015. PMID: 25803356 No abstract available.
• Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma.

  Abramson JS, Chung RT. Abramson JS, et al. JAMA. 2014 Dec 17;312(23):2505-7. doi: 10.1001/jama.2014.16095. JAMA. 2014. PMID: 25514300 No abstract available.
• Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.

  Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, Wu X, Peng J, Xu B, Lin Y, Cao Y, Li H, Lin S, Liu Q, Lin T. Huang H, et al. JAMA. 2014 Dec 17;312(23):2521-30. doi: 10.1001/jama.2014.15704. JAMA. 2014. PMID: 25514302 Clinical Trial.
• Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.

  Coiffier B. Coiffier B. Cancer Invest. 2006 Aug-Sep;24(5):548-52. doi: 10.1080/07357900600815232. Cancer Invest. 2006. PMID: 16939967 Review.
• Antiviral therapies for managing viral hepatitis in lymphoma patients.

  Merli M, Rattotti S, Gotti M, Arcaini L. Merli M, et al. Expert Opin Pharmacother. 2017 Mar;18(4):363-376. doi: 10.1080/14656566.2017.1288718. Epub 2017 Feb 15. Expert Opin Pharmacother. 2017. PMID: 28140702 Review.